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Objective. IA therapy with hyaluronan (HA) is reported to provide symptomatic relief and disease modification in OA. This study assessed the
pathological changes in the synovium of an ovine model of OA and evaluated the effects of two HA preparations on this pathology.
Methods. Eighteen sheep had bilateral lateral meniscectomy to induce OA. Four months post-surgery animals received IA saline or HA
(Hyalgan) weekly for 5 weeks or three injections of an amide derivative of HA (HYADD4-G) every 2 weeks (n¼6 per group). Six months
after meniscectomy, sheep were killed, knee joint synovium processed, scored for pathological change and compared with synovium from
non-operated animals. Sections of synovium from normal and treated joints were also immunostained for TNF- , HSP-47, TGF- , CD44,
connective tissue growth factor (CTGF) or iNOS. HA synthesis by synovial fibroblasts isolated from each OA joint was quantified.
Results. Aggregate scores of pathological change were higher in OA joint synovia compared with controls, with individual measures
of subintimal fibrosis and vascularity predominantly affected. Depth of intimal fibrosis was also significantly higher in meniscectomized joints.
IA treatment with Hyalgan decreased aggregate score, vascularity and depth of fibrosis. HYADD4-G treatment decreased vascularity,
intimal hyperplasia and increased high-molecular weight HA synthesis by synovial fibroblasts. CD44, CTGF or iNOS expression was
increased in the synovial lining of OA joints compared with normal, but there was no significant modulation of this increase by either HA
preparation.
Conclusion. Increased fibrosis and vascularity are hallmarks of pathological change in synovium in this meniscectomy model of OA. Both the
IA HA and an amide derivative of HA reduced aspects of this pathology thus providing a potential mechanism for improving joint mobility and
function in OA.
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Introduction
OA is a multifactorial joint disorder in which ageing, genetic,
hormonal and mechanical factors are all major contributors to its
onset and progression. All of the tissues that constitute the
synovial joint—cartilage, bone ligaments, menisci, joint capsule
and synovial lining—undergo change in OA and contribute to the
degenerative process. While the initial site of injury in OA is still
the subject of debate, degradation of articular cartilage (AC) is the
defining pathological event. The release of fragmented matrix
components from cartilage into SF initiates an inflammatory
response in the synovium and underlying joint capsule [1, 2]. This
synovitis promotes the production of pro-inflammatory mediators
by the resident lining cells, particularly the tissue macrophages.
These cells are an abundant source of cytokines, prostanoids, pro-
coagulant factors, proteinases and oxygen-derived free radicals
including nitric oxide (NO) [3]. These products have profound
effects on the metabolism of joint connective tissues leading to
progression of the AC breakdown and synovial fibrosis, as well as
contributing to joint pain and disability characteristic of OA.
Moreover, recent MRI studies have demonstrated a strong
and unique association between synovitis, capsular thickening
and the severity of knee pain [4, 5], further highlighting
the important role of the synovium in the pathogenesis of OA
[1]. Fibrosis of the synovium occurs in most arthropathies and
may be indicative of epithelial to mesenchymal transitions in
resident fibroblasts leading to increased extracellular matrix
(ECM) deposition [6]. Potential key modulators in the fibrotic
process are heat shock protein-47 (HSP-47), a collagen chaperone
required for collagen synthesis, TGF-  and connective tissue
growth factor (CTGF), both regulators of collagen metabolism
[7]. On the other hand, TNF-  is implicated in prevention of ECM
accumulation [8].
Hyaluronan (HA) confers to SF its unique rheological proper-
ties, which together with lubricin, provides exceptionally efficient
biomechanical protection of AC and peri-articular tissues [9, 10].
In OA joints, SF HA concentration and molecular weight (MW)
are decreased [11], compromising its viscoelasticity and lubricating
ability. In an attempt to restore normality to the SF of OA joints,
Balazs [12] introduced the concept of ‘viscosupplementation’,
whereby a highly purified high-MW HA (HMW-HA) is injected
into the joints of OA patients. Since the introduction of this
therapeutic approach, a large number of HA preparations of
varying MWs and origins have been developed and have been
reported to provide symptomatic relief in the treatment of OA
[13–17]. A recent Cochrane review found that the clinical effects
of IA HA therapy are slower at onset, but more sustained than
with IA corticosteroids [18].
Laboratory and animal model studies with HA have identified
its potential as a disease-modifying OA drug (DMOAD) [19, 20].
Synovial biopsies taken from joints of OA patients treated
with Hyalgan have supported this view [21, 22]. Various
preparations of HA with a range of MWs differentially stim-
ulated synthesis of HMW HA by synovial biopsy cells in culture
[23]. Effects of IA administered HA on the in vivo synthesis
of synovial HA in ovine joints was also MW dependent,
with HMW HA (MW >2000kDa) preparations being less
effective than HA within the MW range of 500–1000kDa [20].
The possible mechanisms by which HA exerts these effects are
still speculative, although CD44 receptors are abundant in
synovium and are intimately involved in HA–ECM inter-
actions [24]. A criticism of using HA as a viscosupplement is
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therefore, modified HA preparations, such as the amide
derivative HYADD4-G, are being manufactured, which have a
longer joint residency but retained SF-like viscoelastic
properties [26].
To date there is little data on the effect of HA on synovial
pathological changes with OA in animal models. We have used a
well-established OA model induced by meniscectomy in sheep to
test efficacy of many potential therapies [27], including several
trials of IA HA preparations which have variously been shown to
reduce cartilage histopathology scores [28, 29], improve gait [30]
and increase osteophytosis [31, 32]. However, synovial pathology
has not routinely been assessed in these studies.
We have developed and validated a histological scoring system
for synovium from OA joints to quantitate pathological changes
in this animal model [33]. In the present study, we confirm that
there are significant changes to ovine synovium after meniscect-
omy and have investigated potential mechanisms for the resulting
pathology. Furthermore, we evaluate the relative effects of IA
Hyalgan and HYADD4-G, an amide derivate of Hyalgan,
on the histopathology, immunohistochemistry and ex vivo endo-
genous HA synthesis of synovium derived from stifle joints of
meniscectomized sheep.
Methods
Animal experimentation
Eighteen aged (7- to 8-yrs old) Merino ewes were subjected to
bilateral lateral meniscectomy as previously described [34, 35].
Two HA preparations were tested vs saline placebo, Hyalgan
(10mg/ml) and HYADD4-G (5mg/ml), both manufactured and
supplied by Fidia Farmaceutici S.p.A., Abano Terme, Italy. Sheep
were randomly allocated prior to surgery to one of the three
treatment groups (n¼6 per group): OAþsaline placebo,
OAþHyalgan and OAþHYADD4-G. From weeks 16 to 20
post-meniscectomy, these groups respectively received bilateral IA
injections of equivalent volume (2ml) of sterile normal saline
(weekly), Hyalgan (weekly) or HYADD4-G (every 2 weeks, at
weeks 16, 18 and 20 post-surgery). IA injections were performed
under short-acting deep sedation (intravenous diazepam at 0.25
mg/kg with ketamine 5mg/kg) using a 21-gauge needle and aseptic
conditions. Post-operatively, animals were transferred to irrigated
pasture (1 hectare paddocks) on the Murdoch University farm,
partially supplemented with lucerne chaff and lupins in order to
maintain constant body condition. Sheep were monitored daily
and killed at 6 months post-meniscectomy. All animal procedures
were approved by the Murdoch University Animal Ethics
Committee (AEC R779/00).
Tissue collection
After opening the knee joint by severing the cruciate and collateral
ligaments, a sample of synovium from the suprapatellar fold was
removed and placed in 10% (v/v) neutral buffered formalin.
Further samples of synovia were removed from the same area and
from adjacent to the femoral condyles, taking care to minimize the
amount of fibrous synovium and subsynovium. These samples
were processed for cell isolation as described subsequently.
Histological processing of synovium
Synovial specimens were fixed in 10% (v/v) neutral buffered
formalin for 24h. Samples were then transferred to 70% (v/v)
ethanol and routinely processed through ascending grades of
ethanol [70–100% (v/v)], cleared in chloroform, then infiltrated
andembeddedinparaffinwax.Sections(4mm)werecutonarotary
microtome and stained with haematoxylin and eosin (H&E).
Histopathology of synovium
H&E stained sections of synovium from both joints of all sheep,
as well as freshly-stained synovium sections from a previous group
of age-matched non-operated control (NOC) sheep, were coded
and scored blind by two observers. The scores ranged from 0 to 3
on the tissue criteria outlined in Table 1. All sections were assessed
by both observers to avoid bias from interobserver variability,
which has been assessed for this scoring protocol and found to be
acceptable [33].
Depth of intimal fibrosis was determined using an eyepiece
graticule of 1cm
2 that, when viewed using a 40  objective, pro-
jected a 250mm
2 grid on each slide. Areas assessed were required
to have a fairly straight intimal edge for at least 250mm, to be at
least 250mm deep and not cover any normal fibrous synovial
tissue. Five randomly selected areas were counted per section at
each observation.
Immunohistology
Immunostaining for CD44, TGF- , CTGF, TNF- , inducible NO
synthase (iNOS) and HSP-47 was performed on sections from one
joint of each sheep as well as age-matched identically processed
NOC synovial specimens. Endogenous peroxidase activity was
initially blocked by incubating the tissue sections with 3% (v/v)
H2O2 for 5min.
Some sections (for TGF- , TNF-  and iNOS immunostaining)
were pre-digested with bovine testicular bovine hyaluronidase
(600U/ml) for 30min at 378C in phosphate buffer, pH 7.4; for
CD44 immunostaining, heat retrieval was performed in 0.01M
citrate buffer, pH6.0 for 20min at 998C (water bath) followed
by 10min cooling at 228C. Non-specific binding was blocked by
incubating the sections in non-serum protein block (DakoCyto-
mation, USA) for 10min at room temperature. Incubations
were performed overnight at 48C with primary antibodies for
CD44 (rat monoclonal; Serotec MCA1449; 1:20 dilution), CTGF
(rabbit polyclonal; Abcam ab6992; 1:1000 dilution), HSP-47
(mouse monoclonal; Stressgen SPA-470; 1:130000 dilution),
iNOS (rabbit polyclonal; Cayman Chemicals 160862; 1:1000
dilution), TGF-  (mouse monoclonal; Abcam ab1279; 1:100
dilution) and TNF-  (rabbit polyclonal; Chemican AB1842;
TABLE 1. Non-parametric scoring of ovine synovial histopathology
Criteria Score Observation
Intimal hyperplasia 0 1–2 layers only
1 3–4 layers, focal
2  5 layers, focal
3  5 layers, diffuse
Lymphocytic/plasmocytic
infiltration
0 None
1 One focus of infiltration
2 2–5 foci of infiltration
3 Diffuse infiltration or >5f o c i
Subintimal fibrosis 0 None
(loose connective tissue
areas only)
1 Light focal collagenous
staining up to 30%
2 Heavy focal staining or total light
diffuse collagenous staining
3 Heavy diffuse collagenous staining
Vascularity 0 0–2 vascular elements
per 100  field
1 3–4 vascular elements
per 100  field
2 5–8 vascular elements
per 100  field
3 >8 vascular elements
per 100  field
Aggregate score (joint) 0–12 Sum of the scores obtained for
the four criteria above
Aggregate score (sheep) 0–24 Sum of the scores obtained for
the four criteria above for
both left and right joints.
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primary antibody and addition of species-matched IgG or serum
at equivalent concentration to primary antibody. The antibodies
were detected using a 30-min incubation with secondary anti-
body cocktail of biotinylated anti-rabbit and anti-mouse, or
biotinylated anti-rat immunoglobulins, followed by a 30-min
streptavidin-conjugated horseradish peroxidase incubation. Stain-
ing was completed after incubation with substrate—chromogen
solution DAB (DakoCytomation, USA) for 5min or NovaRED
(Vector Laboratories, USA) for 15min at room temperature,
which give a brown or red-brown end-product, respectively.
Sections were counter-stained in Mayer’s haematoxylin, washed,
dehydrated, cleared in xylene and mounted.
In order to quantify the effects of the different HA treatments,
sections were assessed by two observers (blinded to treatment
group) for intensity of immunostaining (0–3; 0¼no staining,
1¼mild, 2¼moderate and 3¼marked). Average scores for two
fields per section were calculated.
Isolation of synovial fibroblasts
Non-fixed specimens of synovium were diced finely, washed twice
with phosphate-buffered saline, pH 7.2 (PBS) then resuspended in
12ml sterile 0.2% (w/v) Gibco BRL porcine trypsin/0.1% (w/v)
EDTA in PBS (T&E). After incubation at 378C for 1h, 1ml fetal
bovine serum (FBS) was added to inactivate the trypsin. The
digested tissue was then resuspended in 0.05% (w/v) clostridial
collagenase (Sigma Aldrich) and 0.01% (w/v) DNase I (Sigma
Aldrich) in DMEM/10% FBS and incubated at 378C for 16h.
After washing twice with DMEM/10% FBS, the pellet of ovine
synovial fibroblasts (OSFs) was resuspended in 6ml DMEM/
10% FBS. Three 2ml aliquots of the OSF suspension per joint
were placed into 3 10cm
2 wells of 6-well plates and incubated
at 378C. Media was changed every 2 or 3 days. When the cells
were  70–80% confluent, they were used to determine de novo
HA synthesis as described subsequently.
HA synthesis by synovial fibroblasts
3H-glucosamine (specific activity¼8.80Ci/mmol; GE Healthcare)
was added to DMEM/10% FBS at 1mCi/ml. Two millilitres were
added to each well (2mCi per well) and exactly 24h later, media
was removed from cells, the cells rinsed with PBS and harvested
for DNA determination using a modification of the Hoescht
33258 dye-binding method described by Kim et al. [36] and
Cake et al. [37].
After adjusting the pH to 6.0 with 10ml 1M acetic acid, 50ml
20mM sodium acetate/0.15M NaCl pH 6.0 with and without
5 TRU Streptomyces hyaluronidase (SHase) was added to 500ml
aliquots of each media sample. All samples were incubated at
608C for 3h and then at 948C for 5min.
Changes in the amount of
3H-glucosamine incorporated into
endogenous HA were measured as radioactivity peaks separated
by Superose 6 (GE Healthcare) size exclusion chromatography.
Digested media samples were centrifuged at 18000g for 10min
(room temperature) immediately prior to loading via a 200ml
sample loop and the pre-filtered degassed elution solvent was PBS,
pH 7.2 run at 12ml/h. The column eluent was collected for
determination of radioactivity by scintillation spectometry in
Ecolite (ICN Biochemicals). CPM in hyaluronidase-digested
samples was subtracted from CPM in undigested samples to
obtain CPM specifically due to
3H-hyaluronan. The CPM value
thus obtained for each well was corrected for number of cells
present, as determine by the cellular DNA content. Total HA
synthesised by the cells was determined from all Superose 6
fractions before the total column volume in SHase-digested
fractions whereas HMW-HA was determined from CPM that
voided the column.
Statistical methods
Non-parametric data (histological and immunohistological scor-
ing) was analysed using the Kruskal–Wallis test for multiple
groups and, if significance was found, Mann–Whitney U-tests
for between-group comparisons (n¼12 joints per treatment)
were used.
The  -level was set at 0.05, reducing to 0.03 following
Benjamini–Hochberg post-hoc procedure for multiple compari-
sons [38] to correct for Type 1 errors. For parametric data (intimal
fibrosis and HA synthesis), unpaired Student’s t-tests were per-
formed, with P<0.05 considered to be statistically significant.
Results
Effect of meniscectomy—histological scoring
Marked differences were observed between knee joint synovia
from NOC animals and saline-treated meniscectomized animals.
Subintimal fibrosis (P¼0.0035), vascularity (P¼0.0035) and
aggregate score of the non-parametric criteria (P¼0.0036), were
all significantly higher in OA joint synovia (Table 2). The increase
in intimal hyperplasia was not statistically significant (P¼0.044)
while the increase in cellular infiltrate was highly variable
(P¼0.13). Depth of intimal fibrosis (P¼0.010) was significantly
increased in synovium from meniscectomized saline-injected joints
compared with NOC (Fig. 1).
Effect of meniscectomy—immunohistology
In the synovium of NOC joints, intimal cells and occasional
fibroblastic subsynovial cells were positive for HSP-47. In
contrast, TGF-  and TNF-  were localized to blood vessels as
well as occasional intimal cells. Immunostaining for HSP-47 was
unaltered in any meniscectomized joints, and although a slight
increase in intimal cell staining for TGF-  and TNF-  was
observed in some OA joints, this was highly variable and was not
significant when sections were blindly scored (data not shown).
In NOC sheep, the antibody for CD44 stained the superficial
synovial intima only, with staining deeper into the tissue rarely
seen (Fig. 2D). Occasional lining cells had cell membrane staining
TABLE 2. Histological scores for H&E sections of stifle joint synovium sampled from NOC sheep and OA sheep subjected to various IA treatments (scored as described
in Table 1)
Treatment Intimal hyperplasia Cellular infiltrate Subintimal fibrosis Vascularity Aggregate scores
NOC 2.83 0.31 0.83 0.40 0.33 0.33 3.50 0.43 7.50 0.71
OAþsaline 4.00 0.37 3.33 1.09 3.67 0.49 5.83 0.17 16.8 1.3
P (vs NOC) 0.044 0.13 0.0035 0.0035 0.0036
OAþHyalgan 3.00 0.52 1.67  0.61 3.00 0.45 4.50 0.43 12.2 0.7
P (vs NOC) 1.00 0.27 0.0049 0.14 0.0046
P (vs OAþsaline) 0.14 0.19 0.32 0.020 0.015
OAþHYADD4-G 2.33 0.56 1.83 0.56 3.33 0.80 4.50 0.50 12.0 1.5
P (vs NOC) 0.55 0.098 0.013 0.16 0.053
P (vs OAþsaline) 0.032 0.25 0.87 0.023 0.076
Values are mean  S.E.M, n¼12 joints, P-values by Mann–Whitney U-ranked tests, with P<0.03 statistically significant after Benjamini–Hochberg post-hoc correction. There were no significant
differences between Hyalgan- and HYADD4-G-treated groups (P>0.5).
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was not always clear. In OA joints, the immunostaining was cell
membrane-associated in all cases and appeared to be strongest on
the cell membranes adjacent to the synovial space, with little
staining in the subsynovial tissue. Synovial lining cells and some
cells in the subsynovium were positive for CTGF in NOC joints
(Fig. 2E). Staining appeared to be mainly cytoplasmic and varied
between cells from no staining to very heavy staining within the
same section of tissue. In OA joints, the tissue distribution of
CTGF was similar to NOC but more intense staining was
observed, and in addition some matrix staining was evident that
was not present in the negative control sections. In synovia from
NOC sheep, the antibody for iNOS stained only a very few lining
cells in some specimens (not all) with no ECM or subsynovium
staining in any specimen (Fig. 2F). After meniscectomy, many
lining cells exhibit heavy staining, with some positive cells also
appearing in the subsynovial tissue. There was more intense
antibody staining for CD44, CTGF and iNOS on the synovial
lining of meniscectomized joints when compared with NOC
(all P¼0.004).
Effect of IA HA treatment
IA treatment with either Hyalgan (P¼0.015, significant) or
HYADD4-G (P¼0.076, not significant) decreased the aggregate
scores to the same extent compared with saline treatment
(Table 2). Compared with saline treatment, vascularity was
significantly decreased by both Hyalgan (P¼0.020) or
HYADD4-G (P¼0.023) while intimal hyperplasia was only
reduced by HYADD4-G (P¼0.032, not significant). Subintimal
fibrosis score was not decreased by either HA preparation
(Table 2). In contrast, intimal fibrosis depth was decreased
significantly by Hyalgan (P¼0.028) and not by HYADD4-G
(P¼0.078) compared with saline (Fig. 1). There were no
differences between IA treatments with either Hyalgan or
HYADD4-G in any of the synovial pathological changes
(P>0.5 for all variables measured). Neither of the HA treatments
modulated intensity or distribution of immunostaining for any
of the molecules examined (Fig. 2J–O).
FIG. 1. Depth of fibrosis of the synovial intima (mean  S.D., n¼12 joints per
group). There were no significant differences between IA treatments (P>0.28)
(unpaired Student’s t-test).
FIG. 2. Representative images of immunohistology of ovine synovium from NOC (A–F), saline-treated (G–I), Hyalgan-treated (J–L) or HYADD4-G treated (M–O) joints
stained with negative control antibodies (A–C) or antibodies to CD44 (D, G, J, M); CTGF (E, H, K, N) or iNOS (F, I, L, O) as outlined in Methods section. Bar represents
100mm for all images, which were captured at  200 magnification.
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Preliminary experiments using OSFs established that cells from
this species, unlike the corresponding human and lapine synovial
cells, do not retain their morphology and phenotypic expression
for many passages in culture (data not shown). For this reason,
the HA synthesis by the isolated synovial fibroblasts from each
sheep joint was determined using primary (previously uncultured)
cells. There were no differences in total or HMW-HA synthesis
by the synovial cells from Hyalgan-treated joints compared
with saline treatment (Fig. 3). In contrast, IA treatment
with HYADD4-G showed a trend towards increased quantity
of total HA (P¼0.088, not significant) and a significantly
increased HMW-HA (P¼0.042) synthesis by the ovine synovial
cells when compared with cells from the joints of saline-treated
sheep.
Discussion
We have shown that there are significant pathological changes
in the synovium of sheep 6 months following meniscectomy.
The histological scoring system used was an extension of that
previously described [33, 39] and specifically designed to detect
differences in this ovine model. The changes induced by meniscec-
tomy include increased intimal cells, intimal and subintimal
fibrosis and vascularity when compared with synovium from
unoperated sheep joints, which mimics the synovial pathological
changes reported in human OA synovium [11]. In contrast, there
was no consistent increase in plasma/inflammatory cell infiltra-
tion, which, together with the lack of increased staining for
TNF- , indicates minimal synovial inflammation at this 6-month
time point in this model. It is plausible that meniscectomy may
induce an early synovial inflammation that is mostly resolved by
6 months, leaving thickened intima, subsynovial fibrosis and
increased vascularity as the predominant pathological changes.
This agrees with the minimal synovial changes seen in OA com-
pared with RA in humans [40]. In order to investigate potential
mechanisms for the pathological changes observed we undertook
immunolocalization for a variety of factors known to be involved
in these processes.
Immunohistology revealed increases in CTGF, CD44 and
iNOS 6 months after meniscectomy. CTGF has been implicated as
a major downstream regulator in TGF- -dependent fibrosis,
particularly of liver, lungs, heart and skin (scarring) [41] and other
fibroproliferative diseases. When transfected into the synovial
lining of mouse knee joints, CTGF induced a transient synovial
fibrosis with ECM accumulation [42], and TGF-  has been found
at sites of fibrosis in patients with OA [43]. TGF-  may be
expressed early to initiate matrix accumulation and induce CTGF,
which is then persistently expressed as suggested in a mouse model
of fibrosis [44], which may explain the lack of change in TGF- 
detected at 6 months in our model. HSP-47 is a collagen chap-
erone that increases during fibrosis in other tissues [45], but its
lack of regulation in the current study suggests that the export
of collagen from the cell is not a rate-limiting step in synovial
fibrosis.
CD44, a multivariate transmembrane glycoprotein known to be
the principle cell surface receptor for HA [46], is present in the
synovium [47] and SF [40] of OA patients and levels correlate with
the degree of inflammation but not Kellgren grade [40]. Limited
evidence of inflammation was noted in our sheep model despite
synovial intima staining more strongly for CD44 than normal
joints. The orientation of the CD44 staining to the synovial space
we report in this study has previously been seen in rat temporo-
mandibular joint synovium, where it co-localized with fibroblastic
synoviocytes (Type B) and not macrophage-like (Type A)
cells [48].
The increase in iNOS may be implicated in OA pathology by
increasing NO, that induces inflammation in synovium [49],
apoptosis of synoviocytes [50] and degradation of AC [51]. iNOS
is expressed by many mammalian cells in response to inflamma-
tory stimuli or mediators, such as IL-1 or TNF [52]. Increased
TNF-  from synovium and SFs from OA patients [53] may induce
increased vascularity through its effects on VEGF [54]. However,
despite a mild increase in immunostaining in some joints, there
was no significant difference in staining score for TNF-  in the
ovine synovium (data not shown).
HA treatment is beneficial in OA patients with decreased
pain and increased range of motion [18]. There are a number
of potential mechanisms whereby HA may have these clinical
benefits. There is evidence that HA functions as a DMOAD,
potentially slowing cartilage degradation [20]. Despite previous
studies where HA treatment reduced tibial cartilage lesion size [39]
and histopathology scores [28, 55], there was no evidence of
modulation of AC pathology after either HA treatment in the
present study (data not shown). The lack of chondroprotection in
the present study may be associated with the advanced age of the
sheep used (7–8 yrs compared with 2–4 yrs in previous studies)
and the timing of the HA administration (16 weeks after induction
of OA). Decreased total and HMW-HA in SF is a consistent
finding in OA [11]. IA HA therapy both directly supplements the
endogenous HA concentration and may stimulate the fibroblasts
of the synovium to produce more HA of higher quality [20, 23]. In
the present study, HYADD4-G stimulated the synthesis of
HMW-HA ex vivo and only this HA preparation decreased
intimal hyperplasia, consistent with the inhibitory effect of HMW-
HA on synoviocyte proliferation in vitro [56]. Previously, we
showed that acute application of non-derivatized HA in vitro
increased endogenous HA synthesis by synovial fibroblasts, which
was dependent on the MW of the HA preparation. It is interesting
that this effect was not observed in the present study 5 weeks after
HA injection of non-derivatized HA, possibly due to the presence
of HA turnover/clearance mechanisms that would not be present
in vitro. The enhanced ability of HYADD4-G to remain in the
joint cavity and hence in contact with the synovium could account
for its more potent effects on the MW of endogenous HA
production by synovial fibroblasts isolated 5 weeks after the last
injection.
HA preparations that are of a sufficient HMW have analgesic
properties when injected into both animal and human joints
(reviewed in [57]). This has been confirmed both clinically and
in laboratory experiments measuring neural discharges in nerves
of cat [58] and rat [59] joints. The present results of reduced
vascularization of OA synovium by both HA preparations are
consistent with the well-recognised anti-angiogenic properties
of HMW-HA [60] and could contribute to disease modification
and analgesia.
Increased synovial fibrosis was experimentally measured in
the synovium of patients who reported pain after cruciate
ligament reconstructive surgery [61] and was uniquely correlated
with knee pain in those OA patients with knee symptoms [4].
Neither of the HA preparation decreased the subintimal fibrosis
score that assessed overall fibrosis in the section. However,
Hyalgan decreased intimal fibrosis depth, and this could
contribute to the reduction in OA pain after HA IA treatment
in patients. The reduction in fibrosis seen with the IA HA
injections was not reflected in reduced CTGF levels, suggesting
alternate mechanisms for the anti-fibrotic effect. CTGF has been
shown to up-regulate tissue inhibitor of metalloproteinase-1
(TIMP-1) in mouse synovium [42], potentially preventing collagen
catabolism by MMPs and facilitating matrix accumulation [62].
HMW-HA decreased TIMP-1 expression in isolated human
synovial fibroblasts [63], and hence may allow increased MMP
activity, normalizing collagen turnover and thus preventing the
fibrosis. Whether the injected HA in the present joints may act to
reduce TIMP-1 levels, allowing uninhibited MMP activity to
counteract the effects of CTGF and thus decrease fibrosis requires
further investigation.
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it is rapidly cleared from the synovial cavity, largely via
the lymphatics [64]. In an attempt to prolong the half-life of HA
in the joint, cross-linked or otherwise modified HA prepara-
tions with markedly increased MW and resistance to degradation
have been examined. This research has produced alternative
treatments for OA, which stay longer in the joint, and HA
preparations with potentially different pharmacological properties
[65]. HYADD4-G is a novel amide derivative of 500–730kDa
HA (Hyalgan) where aliphatic amine (hexadecylamine) is bound
to HA at the carboxylic group of the glucuronic acid (2%
substitution). HYADD4-G has been observed to have superior
rheological properties to Hyalgan and to human SF [26]. Overall,
both HA preparations in the current study have a beneficial effect
on synovial pathological changes; however, the potential longer
retention of HYADD4-G, which also induced increased HMW-
HA and decreased intimal hyperplasia with fewer injections, may
suggest potential advantages of this preparation.
There have been a number of reviews of the benefits of IA HA
treatment in OA. One of the most recent systematic reviews of five
HA trial meta-analyses (covering 11–37 studies each) concludes
that this therapy results in modest improvement in validated
outcomes [17], with four of the five meta-analyses rating HA as
beneficial and safe. Contention arises, however, when attempts are
made to explain how HA modulates the disease process, or which
if any, of the various HA preparations are superior. It is clear
from the present study that the actions of IA HA in OA synovium
are multi-factorial. In the present animal model, IA HA (both
Hyalgan or HYADD4-G) reduced the overall pathology of
synovia from meniscectomized joints. Neither of the HA prepara-
tion modified immunostaining of the six potential effector mole-
cules examined. Further studies are necessary to elucidate the
processes by which the different HA treatments are generating
a positive effect in OA synovium.
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